Corrigendum: Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer

Front Med (Lausanne). 2024 Feb 5:11:1375203. doi: 10.3389/fmed.2024.1375203. eCollection 2024.

¹ Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, China.
² Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
³ Department of Neurosurgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China.
⁴ Department of Pathology Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
⁵ Department of Breast Surgery, Affiliated Hospital of Jining Medical University, Jining, China.
⁶ Department of Medical Oncology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fmed.2023.1167676.].

Keywords: DYNLT1; biomarker; breast cancer; immune checkpoint blocking therapy; prognosis.